Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial

• Published in: Cephalalgia Vol. 42; no. 2; pp. 108 - 118
• Main Authors: Reuter, Uwe, Ehrlich, Marc, Gendolla, Astrid, Heinze, Axel, Klatt, Jan, Wen, Shihua, Hours-Zesiger, Peggy, Nickisch, Jacqueline, Sieder, Christian, Hentschke, Christian, Maier-Peuschel, Monika
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.02.2022
• Subjects: Adult; Antibodies, Monoclonal, Humanized; Calcitonin Gene-Related Peptide Receptor Antagonists - therapeutic use; Double-Blind Method; Humans; Migraine Disorders - drug therapy; Migraine Disorders - prevention & control; Original; Topiramate - therapeutic use; Treatment Outcome; Erenumab; migraine; head-to-head study; CGRP; prophylaxis; topiramate

Background We compared the tolerability and efficacy of erenumab, a monoclonal antibody binding to the calcitonin gene-related peptide receptor, to topiramate for migraine prophylaxis in adults. Methods HER-MES was a 24-week, randomised, double-blind, double-dummy, controlled trial conducted in 82 s...